Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fully human CD7 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Beijing Boren Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Fully human CD7 CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy targeting the CD7 antigen, which is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL). Developed by Beijing Boren Hospital, these cells utilize a fully human single-chain variable fragment (scFv) to minimize immunogenicity and are often derived from related donors (allogeneic) to avoid contamination with malignant T-cells and to overcome T-cell aplasia in the patient. In clinical protocols, they are frequently used as a bridge to or in combination with allogeneic hematopoietic stem cell transplantation (allo-HSCT) to achieve deep remission and long-term survival in patients with relapsed or refractory T-cell malignancies.
- Other names
- Donor-derived fully human CD7 CAR-T cellsCD7-targeted CAR-T cellsCD-7-targeted CAR-T cellsCD 7-targeted CAR-T cells
02
Targets
CD7 (CD7 antigen)
Beyond the preview
Go deeper on fully human CD7 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fully human CD7 CAR-T cells.